OEG-CML-001 · NOT_ESTABLISHED
Independent third-party validation of the reported 800VDC / SST deployment is established.
800V DC Data Center Power Architecture
- Evidence cut-off
- 2026-09-20T10:46:47Z
- Claim
- CML-PDRE-001.INDEPENDENT_VALIDATION
VORTEX Activation · Phase 1
Open Evidence Gaps
Six bounded stop points across the three existing public cases. Submit a public URL or document reference that could support, contradict, narrow, or correct one gap.
2 gaps per existing case
What evidence could change the public record?
Submission is not acceptance. Evidence is screened against the stated scope and source requirements.
OEG-CML-002 · NOT_ESTABLISHED
The 800VDC / SST architecture has been replicated by multiple independent entities.
800V DC Data Center Power Architecture
- Evidence cut-off
- 2026-09-20T10:46:47Z
- Claim
- CML-PDRE-001.MULTI_ENTITY_REPLICATION
OEG-BESS-001 · NOT_ESTABLISHED
A named customer sodium-ion stationary BESS site has been commissioned.
Sodium-Ion BESS Commercialization
- Evidence cut-off
- 2026-09-24
- Claim
- SE-BESS-SODIUM-001.NAMED_COMMISSIONED_SITE
OEG-BESS-002 · NOT_ESTABLISHED
Independent field-performance evidence for sodium-ion stationary BESS is established.
Sodium-Ion BESS Commercialization
- Evidence cut-off
- 2026-09-24
- Claim
- SE-BESS-SODIUM-001.INDEPENDENT_FIELD_PERFORMANCE
OEG-ONC-001 · NOT_ESTABLISHED
A hospital-specific aggregate outcome dataset has been acquired for this public NSCLC case.
China Non-Squamous NSCLC Evidence Pathway
- Evidence cut-off
- 2026-09-28
- Claim
- SE-ONC-NSQNSCLC-CN-001.HOSPITAL_AGGREGATE_OUTCOME_DATA
OEG-ONC-002 · SUPPORTED
Ivonescimab with pemetrexed and carboplatin was approved in China for the defined post-EGFR-TKI non-squamous NSCLC indication.
China Non-Squamous NSCLC Evidence Pathway
- Evidence cut-off
- 2026-09-28
- Claim
- SE-ONC-NSQNSCLC-CN-001.IVONESCIMAB_APPROVAL